

This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

Author(s): Solis-Urra, Patricio; Rodriguez-Ayllon, María; Álvarez-Ortega, Miriam; Molina-Hidalgo, Cristina; Molina-Garcia, Pablo; Arroyo-Ávila, Cristina; García-Hermoso, Antonio; Collins, Audrey M.; Jain, Shivangi; Gispert, Juan Domingo; Liu-Ambrose, Teresa; Ortega, Francisco B.; Erickson, Kirk I.; Esteban-Cornejo, Irene

Title: Physical Performance and Amyloid- β in Humans : A Systematic Review and Meta-Analysis of Observational Studies

Year: 2023

Version: Accepted version (Final draft)

Copyright: © 2023 IOS Press

Rights: In Copyright

Rights url: <http://rightsstatements.org/page/InC/1.0/?language=en>

Please cite the original version:

Solis-Urra, P., Rodriguez-Ayllon, M., Álvarez-Ortega, M., Molina-Hidalgo, C., Molina-Garcia, P., Arroyo-Ávila, C., García-Hermoso, A., Collins, A. M., Jain, S., Gispert, J. D., Liu-Ambrose, T., Ortega, F. B., Erickson, K. I., & Esteban-Cornejo, I. (2023). Physical Performance and Amyloid- β in Humans : A Systematic Review and Meta-Analysis of Observational Studies. *Journal of Alzheimer's disease*, 96(4), 1427-1439. <https://doi.org/10.3233/jad-230586>

Physical performance and amyloid beta in humans: A systematic review and meta-analysis of observational studies

Patricio Solis-Urra^{1,2,3}, María Rodríguez-Ayllon⁴, Miriam Álvarez-Ortega¹, Cristina Molina-Hidalgo^{5,6}, Pablo Molina-García^{1,7}, Cristina Arroyo-Ávila¹, Antonio García-Hermoso⁸, Audrey M. Collins⁶, Shivangi Jain⁶, Juan Domingo Gispert^{9,10,11,12}, Teresa-Liu-Ambrose^{13,14,15}, Francisco B Ortega^{1,16,17}, Kirk I Erickson^{5,6}, Irene Esteban-Cornejo^{1,17,18}.

¹PROFITH “PROmoting FITness and Health through physical activity” research group, Sport and Health University Research Institute (iMUDS), Department of Physical and Sports Education, Faculty of Sport Sciences, University of Granada, Granada, Spain.

²Nuclear Medicine Services, "Virgen de Las Nieves", University Hospital, Granada, Spain.

³Faculty of Education and Social Sciences, Universidad Andres Bello, Viña del Mar, Chile.

⁴Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

⁵Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

⁶AdventHealth Research Institute, Neuroscience, Orlando, FL, USA.

⁷Physical Medicine and Rehabilitation Service, Virgen de las Nieves University Hospital, Instituto de Investigación Biosanitaria IBS GRANADA, Granada, Spain

⁸Navarrabiomed, Hospital Universitario de Navarra, IdiSNA, Universidad Pública de Navarra (UPNA), Pamplona, Spain.

⁹BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation, Barcelona, Spain.

¹⁰Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.

¹¹Universitat Pompeu Fabra. Barcelona, Spain.

¹²IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

¹³Centre for Aging SMART at Vancouver Coastal Health, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.

¹⁴Djavad Mowafaghian Centre for Brain Health, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada.

¹⁵Aging, Mobility and Cognitive Neuroscience Laboratory, Department of Physical Therapy, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

¹⁶Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

¹⁷Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, 28029 Madrid, Spain.

¹⁸IBS GRANADA Instituto de Investigación Biosanitaria, Granada, Spain

Corresponding author: Patricio Solis-Urra & Irene-Esteban-Cornejo. Department of Physical Education and Sports, Faculty of Sports Science, University of Granada; Carretera de Alfacar, 21. Granada 18071, Spain; +(34) 958 24 66 51, fax: +(34) 958 24 94 28; email: patriciosolis@ugr.es & ireneesteban@ugr.es

Abstract

Background: Accumulation of amyloid beta (A β) plaques is one of the main features of Alzheimer's Disease (AD). Physical performance has been related to dementia risk and A β and it has been hypothesized as one of the mechanisms leading to greater accumulation of A β . Yet, no evidence synthesis has been performed in humans.

Objective: To investigate the association of physical performance with A β in humans, including A β accumulation on brain, and A β abnormalities measured in cerebrospinal fluid (CSF) and blood.

Method: A systematic review with multilevel meta-analysis was performed from inception to June 16th, 2022. Studies were eligible if they examined the association of physical performance with A β levels, including the measure of physical performance as a predictor and the measure of A β as an outcome in humans.

Results: 7 articles including 2,619 participants were included in the meta-analysis. The results showed that physical performance was not associated with accumulation of A β in the brain (ES= 0.01; 95% CI -0.21 to 0.24; I²= 69.9%), in the CSF (ES= -0.28; 95% CI -0.98 to 0.41; I²= 91.0%) or in the blood (ES=-0.19; 95% CI -0.61 to 0.24; I²= 99.75%). Significant heterogeneity was found across the results suggesting possible effect moderation, but the limited number of studies hindered the opportunity to conduct a moderation analysis.

Conclusion: The association between physical performance and A β is inconclusive. This uncertainty arises from the limited number of studies, study design limitations, and heterogeneity of measurement approaches. More studies are needed to determine whether physical performance is related to A β levels in humans.

Keywords: Alzheimer's disease, Physical performance, Amyloid, Meta-analysis

INTRODUCTION

Alzheimer's disease (AD) is one of the most prevalent medical conditions in older ages [1]. Accumulation of amyloid beta ($A\beta$) plaques is one of the main features of AD, which is related to neurodegeneration and increased risk for memory impairment [2]. The concentration of fibrillar $A\beta$ plaques in the brain can be measured in vivo with Positron Emission Tomography (PET) and specific radiotracers. In addition, alterations in the concentration of $A\beta$ species can be detected in cerebrospinal fluid (CSF) and, more recently, ultra-sensitive techniques have been developed to also measure them in plasma [3]. Typically, alterations in $A\beta_{1-42}$ or the ratio $A\beta_{1-42}/A\beta_{1-40}$ can be detected in CSF before soluble $A\beta$ accumulates into plaques and can be detected through PET imaging.

Several factors have been identified that increase risk for $A\beta$ accumulation, including genetic factors (i.e., APOE $\epsilon 4$ carriers), level and quality of education, cardiometabolic conditions and lifestyle factors [1]. Identifying at-risk populations, such as APOE $\epsilon 4$ carriers, persons with poorer education, poor cardiovascular health or poor lifestyle, is critical to understanding manifestation of clinical symptoms of AD and disease progression. Closely linked with lifestyle factors (e.g., physical activity) are physiological and behavioral measures of physical performance and function. In this review, we adopted the concept of physical performance including physical fitness or physical function tests, which are two interrelated concepts representing the capacity to carry out daily tasks with vigor and alertness, without undue fatigue and with ample energy to enjoy, involving sub-domains such as aerobic fitness, muscular strength, agility, flexibility, mobility, and dexterity, among others [4, 5]. In fact, there are many studies demonstrating an association between indices of better physical performance and greater brain health across the lifespan [6]. Further, higher levels of physical performance are associated with a reduced risk for several neurological diseases, including cognitive decline, AD, and dementia, but the mechanisms by which this occurs remains poorly understood [7, 8]. This is of relevance since physical performance is recognized as an

important marker for physical and brain health associated with several underlying conditions related to aging and AD [9, 10]. Moreover, there is a need to select easy and cheap measurements to implement into clinical practice, with the utility of identifying at-risk people [11].

One possible mechanism explaining the association between physical performance and reduced risk for dementia is that the better lifestyles and health behaviors that are associated with elevated physical performance led to reduced A β accumulation, which in turn could influence cognitive function and dementia risk [12]. Previous reviews have shown that physical exercise (the most effective approach for improving physical performance) reduces production of A β in animal models [12, 13]. In addition, recent evidence reinforces the idea that long-term exercise training attenuates A β accumulation, with the potential capacity to delay the progression of AD in rat models [14]. For instance, mice showing strength gains after exercise also had nearly a 30% reduction in A β in the hippocampus [15]. This is in line with two additional studies reporting a reduction of A β load in rat AD-like models after 6 weeks of exercise [16] and an A β load reduction in a dose-dependent manner by 12 weeks of exercise [17]. However, human studies examining physical performance and A β are scarce and conflicting. While several studies have shown that better physical performance is associated with lower A β accumulation in older adults [18], other studies have found no association [19, 20] or even the opposite association [21]. For instance, whereas several physical performance metrics such as aerobic performance and muscular performance have been negatively associated with blood A β_{42} [18], others, such as gait speed, were not associated with blood markers of amyloid [22]. In addition, greater accumulation of brain A β , as measured by PET, was associated with lower gait speed in older adults without dementia. In contrast, no association with brain A β was found in patients with motor impairments [23]. One possible reason for these inconsistencies is that while animal models are more homogeneous, human studies have greater heterogeneity in physical performance components (i.e., aerobic performance, motor performance, muscular performance), A β measures

(i.e., PET, CSF or blood), and the characteristics of the study samples (e.g., cognitively normal or cognitively impaired). A systematic synthesis and meta-analysis of the existing evidence will contribute to a better understanding of the association of physical performance measures with A β , and it may help to confirm whether changes in physical performance is a risk factor for subsequent cognitive decline and AD.

Overall, two previous narrative reviews have explored the association of physical performance and A β accumulation in older adults [12, 13]. However, no previous systematic reviews have quantitatively synthesized these data in a meta-analysis or examined moderators (physical performance component, A β measurements and sample characteristics) of this relationship in humans. Therefore, the aim of this systematic review and meta-analysis was to investigate the association of physical performance with A β in humans. In addition, if there is enough evidence, we aimed to test the moderating role of physical performance components, A β measurements, and sample characteristics in the relationship between physical performance and A β .

METHOD

Information sources and study selection

The review protocol has been registered on PROSPERO (CRD42020184430). According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [24], all potentially relevant articles were identified through a computerized search of the main electronic databases: PubMed, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trials and SportDiscuss from inception to June 16th, 2022, without any filters being applied. The search strategy and search terms used for all databases is described in **Table S1**. Relevant articles were screened by titles and abstracts by two independent researchers (MAO and CAA) in EndNote. Full-text articles considered acceptable for review were examined to determine final eligibility by the same two

researchers (MAO and CAA). In case of disagreement, a consensus was achieved through discussion, and when required, the opinion of a third researcher (MRA) was considered. No language limitations were applied. In addition to the articles found in the search, reference lists of articles were reviewed.

Eligibility criteria

The review followed the PECOS framework (Population, Exposure, Comparator, Outcomes, Study design) framework. Briefly, inclusion criteria were : 1) Population: all ages; 2) Exposure/Comparator: a physical performance component; 3) Outcomes: A β accumulation assessed in the brain using PET, CSF, or in blood samples; 5) Study design: observational studies (i.e., cross-sectional and prospective cohort studies) and intervention studies (i.e., randomized controlled trial [RCT] and non-randomized controlled trials [non-RCT]) including a measure of association between physical performance (as predictor) and A β (as outcome) were considered eligible for inclusion.

Exclusion criteria were: 1) Population: non-human population; 2) Exposure/comparator: no measure of physical performance; 3) Outcomes: no A β measure; 4) Study design: case-control studies, review articles, letters to the editor, comments, gray literature, case reports, longitudinal, and intervention studies that did not report a cross-sectional association. Studies testing the inverse association (i.e., A β accumulation as exposure, and physical performance as outcome) were excluded. Missing data or necessary additional information were requested from the corresponding authors of the articles. When authors do not provide data to allow calculation of the effect size (ES) of the association of physical performance with A β accumulation, studies were excluded.

Data extraction

Two authors (MAO and PMG) independently extracted and double checked the data from each study. Disagreements were solved by a consensus meeting, and a third investigator (MRA) was consulted for any needed resolutions. The following data were extracted: first author and year of publication,

country of the sample, study design, age, sex, physical performance component, cognitive status, the outcome of interest, and details of adjustment for covariates in the multivariate model (when available).

Evaluation of the risk of bias

The risk of bias was evaluated independently by two authors (MAO and CMH) using the Joanna Briggs Institute Critical Appraisal Tool for Systematic Reviews, which has been used in previous reviews [25]. Any discrepancy was solved in a consensus meeting with PSU, MRA, and IEC. Each item was assigned one of four possible responses: “yes” (criterion met), “no” (criterion not met), “unclear” or “not applicable”. The specific tools included thirteen items for RCTs, nine items for non-RCTs, eleven items for longitudinal studies, and eight items for cross-sectional studies. The studies were categorized with an overall risk of bias score as used in previous studies [25]. Specifically, the studies were considered as “low risk” when 75% of items were scored as “yes” (criterion met). The answer “not applicable” was excluded from the percentage calculation.

Multi-level Meta-analysis

A multi-level meta-analysis to study the association of physical performance and $A\beta$ was performed, using R Statistical Software (version 4.2.2), and the *metafor* package version 3.8.1. For studies reporting associations between physical performance and $A\beta$, correlation coefficients were extracted, along with sample size. When correlation values were not provided, but studies met the inclusion criteria, correlation coefficients were calculated using the available data according to the analysis presented using *esc* package 0.5.1. Statistical significance was set at a p-value less than 0.05. Heterogeneity was assessed using the Q-statistic (with $p < 0.10$ suggesting statistically significant heterogeneity) and I^2 statistic (the percentage of total variability attributed to between-study heterogeneity). Funnel plots of the ES against the standard error (SE) of ES were visually inspected

for small-sample bias, and Egger's test values with 95% CI for funnel plot asymmetry were calculated. Publication bias was considered to be present when the funnel plot appeared asymmetrical and the intercept of the Egger's test was significantly different from zero ($p < 0.10$) [26, 27].

RESULTS

Studies retrieved

The systematic search yielded 2,012 references, of which 1,527 were unique. **Figure 1** shows the study selection process and literature search results. After screening titles and abstracts 1,443 documents were excluded and 84 full-text articles were retained for further screening. After revising the full-text of the studies, 7 unique studies were included for analysis. The specific reason for exclusion is shown in **Table S2**. No studies were excluded due to their methodological characteristics. No additional studies met the inclusion criteria after checking article's reference lists.

Study characteristics

Study characteristics are shown in **Table 1**. In total, 7 independent samples were included in the systematic review. Specifically, data from 2,619 participants were included in the meta-analysis. The sample size ranged from 20 [23] to 2,366 participants [22], and all studies included at least 35 % females [23], with the greatest percentage of female participation at 57.4 % [28]. Overall, the mean age ranged from 57.3 [18] to 92.4 years [29]. Additionally, 4 studies reported data of patients with any neurological condition/risk [18, 20, 23, 30], 2 studies included cognitively normal participants [22, 28], and 1 study included a mix of cognitively normal and cognitively impaired participants [29].

Most studies assessed physical performance using components of ambulation or motor ability. Six studies included motor ability [20, 22, 23, 28-30]. These studies assessed motor ability by gait speed [20, 22, 23, 28], global agility parameters [30], or the total score of the Short Physical Performance Battery, a commonly used measure in geriatric medicine to provide an index of physical

function and mobility [29]. One study included aerobic capacity using a fitness test (Rockport Fitness Walking Test) as a measure of physical performance [18]. Three studies included specific muscular strength measurements, both upper (i.e., handgrip strength test or arm curl test) and lower (chair stand test) body measurements, as indicators of physical performance [18, 22, 29].

Three studies assessed A β in the brain using a PET scan [23, 28, 29], using [18F]florbetapir or [18F]flutemetamol [23], [11C]PiB [28] and [18F]flutemetamol ligands [29]. While two studies used the distribution volume ratio values with the cerebellum gray matter as reference as outcome [28, 29], 1 study used centiloid values with the whole cerebellum as reference as outcome [23]. In addition, two studies assessed A β in CSF [20, 30] with one of these studies not reporting information related to the assay, and 1 was assayed using a high sensitivity ELISA technique. Finally, 2 studies assessed A β in blood [18, 22] using a high sensitivity ELISA technique in plasma [22] and serum [18] samples. None of the studies used Mass Spectrometry for measurement of A β in blood samples.

Finally, the most common confounding variables used as covariates in statistical models were age, sex, and educational level [22, 29, 30], and 4 studies reported unadjusted analyses without accounting for the potential influence of other variables [18, 20, 23, 28].

Risk of bias assessment

The risk of bias assessment is presented item by item in **Table S3**. Briefly, most studies met the criteria of clarity of a well-defined sample size. On the other hand, the criteria with the lowest compliance were those related to the validity and reliability of the outcome measurement. The risk of bias assessment for each study is presented in **Table S4**. Briefly, 5 studies were categorized as low risk, while 2 studies were categorized as high risk (25% of items were scored as “no” or “unclear”). The publication bias based on visual observation of the funnel plot and Egger’s tests is shown in

Figure 2, corresponding to brain (Coef: -0.057; $p = 0.522$; 95% CI: from -8.677 to 17.096), CSF (Coef: -34.641; $p = 0.001$; 95% CI: from -55.781 to -13.500) and blood measures (Coef: -18.212; $p = 0.001$; 95% CI: from -29.147 to -7.276).

Meta-analysis of included studies

The association between physical performance and A β was investigated in 7 observational studies corresponding to 21 different ESs. From all ESs, 10 ESs corresponded to motor ability, 9 to muscular strength, and 2 corresponded to aerobic capacity. In addition, 5 ESs were derived from the brain (using PET), 13 were assessed in blood samples (6 of them A β 42 isoform, 4 A β 40 isoform, and 3 A β 42/A β 40), and 3 were derived from the CSF. **Figure 3, 4 and 5** shows the overall effect meta-analysis of physical performance on A β measurements corresponding to measures on brain (PET), CSF and blood, respectively. The overall effect was not significant on brain (**figure 3**; pooled standardized effect= 0.01; 95% CI -0.21 to 0.24; $I^2 = 69.9\%$), CSF (**figure 4**; pooled standardized effect= -0.28; 95% CI -0.98 to 0.41; $I^2 = 91.0\%$) or blood (**figure 5**; pooled standardized effect= -0.19; 95% CI -0.61 to 0.24; $I^2 = 99.75\%$). In addition, sensitivity analysis for the overall effect on blood excluding A β 40 remains non-significant (pooled standardized effect= -0.15; 95% CI -0.66 to 0.36; $I^2 = 99.46\%$). Moderation analysis was not conducted due to the limited number of ESs.

DISCUSSION

The aim of the present work was to synthesize the current evidence and perform a systematic and quantitative review to determine the relationship between physical performance and A β in humans. Our main finding suggests that the association between measures of physical performance and A β levels is inconclusive, due to the limited number of studies included and the high heterogeneity in the measures. Additionally, there is insufficient data to test for various moderators (e.g., sample characteristics) of the association physical performance components and A β .

The amyloid pathway has been suggested as one possible mechanism explaining the association between physical performance measures and cognitive function in late adulthood [31, 32]. In humans, better physical performance could also influence A β changes [33]. Our review of the existing literature indicates that there is no consistent evidence that physical performance is associated with A β accumulation in the brain, and a small non-significant negative association with A β abnormalities in blood and CSF, respectively. The direction of the association between physical performance and A β seems to be controversial, with several methodological factors that likely contribute to the heterogeneity such as the measurement method for A β , the physical performance measurement, and sample characteristics. For example, an indirect laboratory measure of physical performance (e.g., energetic cost of walking, less is indicative of better performance) but not gait speed was positively linked with brain A β accumulation [28]. In patients with Parkinson's disease, lower levels of CSF A β 42 predicted worse physical performance [34], while in patients with idiopathic normal pressure hydrocephalus, higher physical performance (gait velocity) was associated with lower CSF A β 42 and A β 40 levels [35]. However, there is insufficient and inadequate data to reach definitive conclusions due to the limited number of studies and heterogeneity of measurement approaches. Thus, well-controlled studies with larger sample sizes and standardized and harmonized measures in humans are needed to establish more definitive conclusions and to understand the clinical significance of any association between physical performance and A β .

In humans, the accumulation of A β in the brain as measured by PET is considered a gold-standard, but the results from measuring A β in CSF and blood are increasing [36-38]. Various factors, including assay methodologies and differences in clearance of A β from the brain, may contribute to these discrepancies. For instance, there is evidence of a positive association between plasma A β 42 and CSF A β 42, both showing lower levels in AD patients [39]. In contrast, there is also evidence showing that plasma A β 42 was inversely correlated with CSF A β 42 in AD patients [40],

which might be explained by differences in the influx of A β 42 from the brain to the CSF and from the brain to the peripheral circulatory system [37, 38, 41-43]. Interestingly, it is also important to consider that other tissues may also contribute to peripheral A β production [42, 44]. Also, while blood biomarkers may be more sensitive to changes in A β than CSF biomarkers [42], different detection methods have different levels of sensitivity and specificity [40]. For example, high-performance mass spectrometry analysis provides better sensitivity and specificity than commercial ELISAs [45]. Specifically, our results show a high variability of approaches for assessing A β accumulation and A β abnormalities in terms of ligands, processing and assays. Thus, these methodological factors may provide an explanation for the heterogeneous results of our analysis.

Regarding physical performance measures, most were “walking” or “gait” tests and were included in all studies, while muscular strength was included only in 3 different studies. Regarding study sample characteristics, there is high variability in amyloid accumulation between cognitively normal and cognitively impaired individuals, and amyloid clearance is more efficient in patients with higher A β baseline levels [46]. In addition, Tsai et al., explored the interaction of APOE ϵ 4 carriers in the relationship between physical performance and A β , and found that the association of physical performance with A β 42 was only significant in APOE ϵ 4 carriers [18]. However, we could not perform moderation analysis in this review due to the limited number of studies in each assessment of A β , the small sample sizes include in the studies, the lack of power due to the limited number of ESs in the cognitively impaired group, and the high variability in genetic, disease, and baseline amyloid status. Therefore, further studies are needed to test whether physical performance is associated with brain, blood, and CSF biomarkers of amyloid, including studies with larger sample sizes and more homogeneous sample and measurement methods. This is particularly important for blood biomarkers, since they might be more clinically available, less invasive, and more conducive for clinical trials than CSF and PET biomarkers [42].

This systematic review and meta-analysis has several limitations. First, only 7 studies met the inclusion criteria and were included. Further, we focused our inclusion criterion to studies examining the association in only one direction (physical performance as a predictor of A β levels), but there is evidence suggesting the opposite association - that amyloid accumulation could influence physical performance measures. In this regard, while acknowledge that physical performance detrimental might be a consequence of amyloid pathology, our main interest is investigating the physical performance measures as potential preventive and therapeutic strategies for cognitive decline. Further studies are needed with focus in reveal the reverse causality in these measures. Furthermore, the lack of consistency across studies, such as variations in sample sizes, hinders the reliability of the results and restricts the extent of the conclusions. For instance, Jacob et al. [22] conducted their research on physical function and plasma biomarkers with a notably larger sample size compared to the other studies. However, despite this limitation, our review specifically concentrates on the relationship between physical performance and A β , encompassing all tissues. In consideration of these mixed findings, more standardized research protocols are needed to understand the role of physical performance in modulating A β levels in middle-aged and older adults. Finally, motor ability as a measure of functional mobility, was the physical performance component most considered in the included studies, and the associations for the other physical performance components (i.e., aerobic capacity and muscular strength) were based on a small number of subjects. Considering that aerobic capacity and muscular strength are the most important components related to health [47], more evidence including these components is needed. The strength of the present systematic review is that we provided a synthesis of the association of several physical parameters with measures of amyloid across several tissues (brain, blood, CSF), and provided a comprehensive overview of the available evidence with a focus on understanding the role of physical performance on amyloid accumulation.

Literature gaps and future research

- More studies are needed to test the association of physical performance with A β levels, with larger sample sizes and including clearly articulated measurements of physical performance and A β levels.
- Due to the possibility of bi-directionality, longitudinal cohort studies with physical performance measures and A β for at least two-time points are needed to determine the possibility of reverse causality and to confirm the predictive value of physical fitness on AD progression.
- More studies are needed to disambiguate whether sample characteristic such as cognitive status or type of tissue or assay, might moderate the association of physical performance and A β levels.
- In addition to the A β path, more research is needed to unravel the potential mechanisms linking physical performance with cognitive decline trajectories in the elderly.

In conclusion, the results suggest that the association between physical performance and A β levels in humans remains inconclusive. This uncertainty arises from the limited number of studies, design limitations, and heterogeneity of measures; which in turn precludes the exploration of potential moderating variables (i.e., physical performance measures, A β measurements and sample characteristics). This information might be considered in further studies investigating the association of physical performance and A β levels in humans.

Acknowledgments

The authors have no acknowledgments to report.

Funding

This study is supported by grant RTI2018-095284-J-100 funded by MCIN/ AEI /10.13039/501100011033/ and by “ERDF A way of making Europe”, and by grant RYC2019-027287-I funded by MCIN/ AEI /10.13039/501100011033/ and “ESF Investing in your future”. PS-U is supported by a “Margarita Salas” grant from the Spanish Ministry Universities. Plan Andaluz de Investigación (PAIDI) (Convocatoria 2020, Ref: P20_00124) 2021-2022. Ministerio de Economía y Competitividad - Proyectos I+D+I RETOS (Convocatoria 2020, Ref: PID2020-120249RB-I00). EXERNET Research Network on Exercise and Health (DEP2005-00046/ACTI; 09/UPB/19; 45/UPB/20; 27/UPB/21)". The sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of data, in the preparation of the manuscript or in the review or approval of the manuscript.

Conflict of Interest

JDG has received research support from GE Healthcare, Roche Diagnostics, Hoffmann-La Roche and has received speaker/consultant fees from Biogen, Roche Diagnostics, Philips Nederlands and Life-Molecular Imaging.

Data availability

The data utilized in the analysis can be requested from the corresponding authors.

REFERENCES

- [1] Gustavsson A, Norton N, Fast T, Frolich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, Lanman L, Chadha AS, van der Flier WM (2022) Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimers Dement*.
- [2] Rischel EB, Gejl M, Brock B, Rungby J, Gjedde A (2022) In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails. *Alzheimers Dement*.
- [3] Blennow K (2021) Phenotyping Alzheimer's disease with blood tests. *Science* **373**, 626-628.
- [4] Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP, American College of Sports M (2011) American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* **43**, 1334-1359.
- [5] van Lummel RC, Walgaard S, Pijnappels M, Elders PJ, Garcia-Aymerich J, van Dieen JH, Beek PJ (2015) Physical Performance and Physical Activity in Older Adults: Associated but Separate Domains of Physical Function in Old Age. *PLoS One* **10**, e0144048.
- [6] Erickson KI, Donofry SD, Sewell KR, Brown BM, Stillman CM (2022) Cognitive Aging and the Promise of Physical Activity. *Annu Rev Clin Psychol* **18**, 417-442.
- [7] Farrell SW, Abramowitz AR, Willis BL, Barlow CE, Weiner M, Falkowski J, Leonard D, Pavlovic A, DeFina LF (2018) The Relationship between Cardiorespiratory Fitness and Montreal Cognitive Assessment Scores in Older Adults. *Gerontology* **64**, 440-445.
- [8] Sujkowski A, Hong L, Wessells RJ, Todi SV (2022) The protective role of exercise against age-related neurodegeneration. *Ageing Res Rev* **74**, 101543.
- [9] Voss MW, Jain S (2022) Getting fit to counteract cognitive aging: evidence and future directions. *Physiology* **37**, 197-206 %@ 1548-9213.
- [10] Vidoni ED, Honea RA, Billinger SA, Swerdlow RH, Burns JM (2012) Cardiorespiratory fitness is associated with atrophy in Alzheimer's and aging over 2 years. *Neurobiol Aging* **33**, 1624-1632.
- [11] Esteban-Cornejo I, Ho FK, Petermann-Rocha F, Lyall DM, Martinez-Gomez D, Cabanas-Sanchez V, Ortega FB, Hillman CH, Gill JMR, Quinn TJ, Sattar N, Pell JP, Gray SR, Celis-Morales C (2022) Handgrip strength and all-cause dementia incidence and mortality: findings from the UK Biobank prospective cohort study. *J Cachexia Sarcopenia Muscle* **13**, 1514-1525.
- [12] Vasconcelos-Filho FSL, da Rocha Oliveira LC, de Freitas TBC, de Pontes P, da Rocha ESRC, Chaves EMC, da Silva CGL, Soares PM, Ceccatto VM (2021) Neuroprotective mechanisms of chronic physical exercise via reduction of beta-amyloid protein in experimental models of Alzheimer's disease: A systematic review. *Life Sci* **275**, 119372.
- [13] Brown BM, Peiffer J, Rainey-Smith SR (2019) Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. *Ageing Res Rev* **50**, 9-18.
- [14] Yang L, Wu C, Li Y, Dong Y, Wu CY, Lee RH, Brann DW, Lin HW, Zhang Q (2022) Long-term exercise pre-training attenuates Alzheimer's disease-related pathology in a transgenic rat model of Alzheimer's disease. *Geroscience* **44**, 1457-1477.
- [15] Pena GS, Paez HG, Johnson TK, Halle JL, Carzoli JP, Visavadiya NP, Zourdos MC, Whitehurst MA, Khamoui AV (2020) Hippocampal Growth Factor and Myokine Cathepsin B Expression following Aerobic and Resistance Training in 3xTg-AD Mice. *Int J Chronic Dis* **2020**, 5919501.
- [16] Ozbeyli D, Sari G, Ozkan N, Karademir B, Yuksel M, Cilingir Kaya OT, Kasimay Cakir O (2017) Protective effects of different exercise modalities in an Alzheimer's disease-like model. *Behav Brain Res* **328**, 159-177.
- [17] Moore KM, Girens RE, Larson SK, Jones MR, Restivo JL, Holtzman DM, Cirrito JR, Yuede CM, Zimmerman SD, Timson BF (2016) A spectrum of exercise training reduces soluble A β in a dose-dependent manner in a mouse model of Alzheimer's disease. *Neurobiol Dis* **85**, 218-224.
- [18] Tsai CL, Erickson KI, Sun HS, Kuo YM, Pai MC (2021) A cross-sectional examination of a family history of Alzheimer's disease and ApoE epsilon 4 on physical fitness, molecular biomarkers, and neurocognitive performance. *Physiol Behav* **230**, 113268.

- [19] de Souto Barreto P, Cesari M, Rolland Y, Salabert AS, Payoux P, Andrieu S, Vellas B, Group MS (2017) Cross-Sectional and Prospective Associations Between beta-Amyloid in the Brain and Chair Rise Performance in Nondementia Older Adults With Spontaneous Memory Complaints. *J Gerontol A Biol Sci Med Sci* **72**, 278-283.
- [20] Knapstad MK, Steihaug OM, Aaslund MK, Nakling A, Naterstad IF, Fladby T, Aarsland D, Giil LM (2019) Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study. *J Geriatr Phys Ther* **42**, E122-E128.
- [21] Schirinzi T, Di Lorenzo F, Sancesario GM, Di Lazzaro G, Ponzo V, Pisani A, Mercuri NB, Koch G, Martorana A (2018) Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. *J Alzheimers Dis* **64**, 525-532.
- [22] Jacob ME, O'Donnell A, Samra J, Gonzales MM, Satizabal C, Pase MP, Murabito JM, Beiser A, Seshadri S (2022) Grip Strength, Gait Speed and Plasma Markers of Neurodegeneration in Asymptomatic Middle-aged and Older Adults. *JOURNAL OF FRAILTY & AGING*.
- [23] Bommarito G, Garibotto V, Frisoni GB, Ribaldi F, Stampacchia S, Assal F, Armand S, Allali G, Griffa A (2022) The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging. *J Alzheimers Dis*.
- [24] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Syst Rev* **10**, 89.
- [25] Molina-Garcia P, Migueles JH, Cadenas-Sanchez C, Esteban-Cornejo I, Mora-Gonzalez J, Rodriguez-Ayllon M, Plaza-Florido A, Vanrenterghem J, Ortega FB (2019) A systematic review on biomechanical characteristics of walking in children and adolescents with overweight/obesity: Possible implications for the development of musculoskeletal disorders. *Obes Rev* **20**, 1033-1044.
- [26] Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**, 629-634.
- [27] Habeck CW, Schultz AK (2015) Community-level impacts of white-tailed deer on understory plants in North American forests: a meta-analysis. *AoB Plants* **7**.
- [28] Dougherty RJ, Ramachandran J, Liu F, An Y, Wanigatunga AA, Tian Q, Bilgel M, Simonsick EM, Ferrucci L, Resnick SM, Schrack JA (2021) Association of walking energetics with amyloid beta status: Findings from the Baltimore Longitudinal Study of Aging. *Alzheimers Dement (Amst)* **13**, e12228.
- [29] Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, Ten Kate M, Gordon MF, Novak G, Barkhof F, van Berckel BNM, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ (2021) What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. *J Gerontol B Psychol Sci Soc Sci* **76**, 1499-1511.
- [30] Hatcher-Martin JM, McKay JL, Pybus AF, Sommerfeld B, Howell JC, Goldstein FC, Wood L, Hu WT, Factor SA (2021) Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis. *NPJ Parkinsons Dis* **7**, 105.
- [31] Elsworth RJ, Dunleavy C, Whitham M, Aldred S (2022) Exercise for the prevention of Alzheimer's Disease: multiple pathways to promote non-amyloidogenic A β PP processing. *Aging and Health Research*, 100093 %@ 102667-100321.
- [32] Liang YY, Zhang LD, Luo X, Wu LL, Chen ZW, Wei GH, Zhang KQ, Du ZA, Li RZ, So KF, Li A (2022) All roads lead to Rome - a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer's disease. *Neural Regen Res* **17**, 1210-1227.
- [33] Schultz SA, Boots EA, Almeida RP, Oh JM, Einerson J, Korcarz CE, Edwards DF, Kosciak RL, Dowling MN, Gallagher CL, Bendlin BB, Christian BT, Zetterberg H, Blennow K, Carlsson CM, Asthana S, Hermann BP, Sager MA, Johnson SC, Stein JH, Okonkwo OC (2015) Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. *J Int Neuropsychol Soc* **21**, 841-850.
- [34] Kim R, Lee J, Kim HJ, Kim A, Jang M, Jeon B, Kang UJ (2019) CSF beta-amyloid42 and risk of freezing of gait in early Parkinson disease. *Neurology* **92**, e40-e47.

- [35] Lukkarinen H, Jeppsson A, Wikkelso C, Blennow K, Zetterberg H, Constantinescu R, Remes AM, Herukka SK, Hiltunen M, Rauramaa T, Nagga K, Leinonen V, Tullberg M (2022) Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. *Fluids Barriers CNS* **19**, 11.
- [36] Milà-Alomà M, Suárez-Calvet M, Molinuevo JL (2019) Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. *Therapeutic advances in neurological disorders* **12**, 1756286419888819 %@ 1756286419881756-1756286419882864.
- [37] Zetterberg H (2019) Blood-based biomarkers for Alzheimer's disease-An update. *J Neurosci Methods* **319**, 2-6.
- [38] Toombs J, Zetterberg H (2020) In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease. *Brain Commun* **2**, fcaa054.
- [39] Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D, Tan Hehir CA, Baker D, Blennow K, Hansson O (2016) Plasma beta-amyloid in Alzheimer's disease and vascular disease. *Sci Rep* **6**, 26801.
- [40] Teunissen CE, Chiu MJ, Yang CC, Yang SY, Scheltens P, Zetterberg H, Blennow K (2018) Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer's Disease. *J Alzheimers Dis* **62**, 1857-1863.
- [41] Kazim SF, Sharma A, Saroja SR, Seo JH, Larson CS, Ramakrishnan A, Wang M, Blitzer RD, Shen L, Pena CJ, Crary JF, Shimoda LA, Zhang B, Nestler EJ, Pereira AC (2022) Chronic Intermittent Hypoxia Enhances Pathological Tau Seeding, Propagation, and Accumulation and Exacerbates Alzheimer-like Memory and Synaptic Plasticity Deficits and Molecular Signatures. *Biol Psychiatry* **91**, 346-358.
- [42] Kang J, Tian Z, Wei J, Mu Z, Liang J, Li M (2022) Association between obstructive sleep apnea and Alzheimer's disease-related blood and cerebrospinal fluid biomarkers: A meta-analysis. *J Clin Neurosci* **102**, 87-94.
- [43] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 280-292.
- [44] Kent SA, Spires-Jones TL, Durrant CS (2020) The physiological roles of tau and Abeta: implications for Alzheimer's disease pathology and therapeutics. *Acta Neuropathol* **140**, 417-447.
- [45] Pedrini S, Chatterjee P, Nakamura A, Tegg M, Hone E, Rainey-Smith SR, Rowe CC, Dore V, Villemagne VL, Ames D, Kaneko N, Gardener SL, Taddei K, Fernando B, Martins I, Bharadwaj P, Sohrabi HR, Masters CL, Brown B, Martins RN (2022) The Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults. *Front Aging Neurosci* **14**, 771214.
- [46] Karran E, De Strooper B (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. *Nat Rev Drug Discov* **21**, 306-318.
- [47] Kandola AA, Osborn DPJ, Stubbs B, Choi KW, Hayes JF (2020) Individual and combined associations between cardiorespiratory fitness and grip strength with common mental disorders: a prospective cohort study in the UK Biobank. *BMC Med* **18**, 303.




Figure 1. Flow diagram for study selection

Table 1. Summary of studies investigating the association of physical performance and amyloid beta accumulation (n= 7).

First author, Year; Country	Risk of bias	Study design	Target population (Age [range])	N (% females)	Physical function/fitness; Assessment instruments	A β markers	Method; Instrument/tracer	Covariates
Bommarito et al. 2022; Switzerland	Low	Cross-sectional	Participants with cognitive complains (73.2 \pm 6.4) [Older adults]	20 (35%)	Gait speed; Normal walking using 12-camera optoelectronic system	A β	PET; [18F]florbetapir or [18F]flutemetamol	Age
Dougherty et al. 2021; USA	Low	Cross-sectional	Cognitively normal participants without dementia (77.5 \pm 8.4) [Older adults]	149 (56%)	Gait speed and energetic cost of walking; Usual gait over a 6-m course in an uncarpeted corridor, Usual comfortable pace 20-m	A β	PET; [11C]PiB	Age, sex, years of education, race height, body composition, comorbid conditions, and APOE ϵ 4 carrier status
Hatcher-Martin et al. 2021; USA	High	Cross-sectional	Parkinson disease patients with FoG (70.7 \pm 8.3); without FOG (70.4 \pm 10.1); healthy controls (74.4 \pm 10.0) [$>$ 18]	12 (67%); 19 (37%); 12 (8%); All: 43 (37.2%)	FoG; levodopa challenge paradigm; Timed Up & Go; MDS-UPDRS-III criteria	A β 42	CSF; INNO-BIA AlzBio3, Luminex technology;	Age, sex and duration of disease
Jacob et al. 2022; USA	Low	Cross-sectional	Cognitively normal participants (60.55 \pm 9.34) [34-88]	2366 (54%)	Fast walking speed, and muscular strength; 4-meter walk, 5 chair stand test, hand dynamometer	A β 42, A β 40, A β 42/A β 40	Plasma; INNO-BIA AlzBio3, Luminex xMap technology;	Age, sex, diabetes, cardiovascular disease, atrial fibrillation, smoking, APOE ϵ 4 carrier status, systolic blood pressure, waist-to-hip ratio, total cholesterol level, PA index and plasma homocysteine levels
Knapstad et al. 2019; Norway	Low	Cross-sectional	The participants with a recent onset of cognitive symptoms (64 \pm 9) [40-80]	69 (52%)	Usual and fast gait speed; 10-m dynamic walking speed test	A β 42	CSF; ND	Age, sex, years of education and BMI
Legdeur et al. 2021; 11 cohorts in Europe	Low	Cross-sectional	84 cognitively normal and 38 cognitively impaired participants (92.4 \pm 2.8) [90+]	84 (53.6%); 38 (65.8%); All 122 (57.4%)	General physical performance, muscular strength; SPPB, hand dynamometer	A β	PET; [18F]flutemetamol	Age, sex and education
Tsai et al. 2021; USA	Low	Cross-sectional	Individuals with a family history of Alzheimer disease: Non-APOE-4 (59.73 \pm 5.69); APOE-4 (57.32 \pm 7.26) [38-73]	22 (50%); 22 (50%)	Aerobic fitness, muscular strength; Rockport Fitness Walking Test, Arm Curl and 30-s chair stand test (from SFPF battery)	A β 42, A β 40	Serum; Single Molecule Counting (SMC $\text{\textcircled{R}}$) Immunoassay Technology	Age

Abbreviations: APOE-4: Apolipoprotein E; A β : amyloid beta; BMI: body mass index; CSF: Cerebrospinal fluid; FoG: Freezing of gait; SPPB: Short Physical Performance Battery; GXT: Physician-supervised graded exercise test; HABCPPB: Health ABC Physical Performance Battery; MAPT: The Multidomain Alzheimer Preventive Trial; MDS-UPDRS: Revised Unified Parkinson's Disease Rating Scale; MMSE: Mini Mental State Examination; ND: Not disclosed; NFOG-Q: New Freezing of Gait Questionnaire; PD: Parkinson disease; PET: Positron Emission Tomography; PIB: Pittsburgh Compound B; REM: Rapid eye movement; RSEGCD: The Rating Scale for Gait Evaluation in Cognitive Deterioration; SPPB: Short Physical Performance Battery; SUVR: standardized uptake value ratio; TUGT: Timed Up and Go Test; UPDRS: Unified Parkinson's Disease Rating Scale. MDS: Meso Scale Discovery; SFPF: Senior Functional Physical Fitness; PA: Physical activity.




Figure 2. Funnel plots to show publication bias in the association of physical performance with amyloid beta on Brain (PET), CSF and blood. Diagonal lines represent pseudo-95% confidence intervals. The y-axis represents the standard error (weight in the pooled analysis). The x-axis shows the effect size; thus, the vertical line represents the calculated estimated effect of amyloid beta.




Figure 3. Overall effect meta-analysis of physical performance on amyloid beta accumulation on Brain (PET). A β : Amyloid beta. I^2 : Heterogeneity. ECW: Energetic cost of walking. SPPB: Short physical performance battery. MCR: Motoric Cognitive Risk classified with gait speed.




Figure 4. Overall effect meta-analysis of physical performance on amyloid beta abnormalities in CSF. A β : Amyloid beta. I^2 : Heterogeneity. FOG: Freezing of gait.




Figure 5. Overall effect meta-analysis of physical performance on amyloid beta abnormalities in blood. A β : Amyloid beta. I^2 : Heterogeneity. FOG: Freezing of gait.

Table S1. Search strategy.

Databases	Search strategy
Web of Science, PubMed, SPORTDiscuss PsycINFO, Cochrane Central Register of Controlled Trials, until 16 June 2022.	("A-beta" OR "amyloid" OR "A β " OR "beta-Peptide" OR "beta- Protein*" OR " β -protein" OR Amyloidosis) AND ("Physical Fitness" OR "Physical Conditioning" OR "Muscle Strength" OR "Muscular strength" OR "Muscular fitness" OR "Musculoskeletal fitness" OR "Range of Motion" OR "Postural Balance" OR "Musculoskeletal Equilibrium" OR "Postural Equilibrium" OR "Joint range of motion" OR "Joint flexibility" OR "Range of motion" OR "Cardiorespiratory fitness" OR "Cardiovascular fitness" OR "Aerobic fitness" OR "Aerobic capacity" OR "Maximal oxygen consumption" OR "VO2max" OR "Running Speed" OR "Agility" OR "Motor Fitness" OR "Motor ability" OR gait OR "standing balance" OR "motor slowing" OR "functional mobility" OR "physical function" OR "physical functioning" OR "physical performance" OR "physical ability" or "intrinsic capacity")

Table S2. Excluded articles (N=77)

Reasons	Number of articles	References
Wrong predictor	25	Allali et al., 2018; Dunkelmann et al., 2018; Lacroix et al., 2017; Lalonde et al., 2012; Law et al., 2019; Lilamand et al., 2018; Lilamand et al., 2016; Mollica et al., 2019; Mukhamedyarov M et al., 2009 ; Stover et al., 2015; Tsai et al., 2019; Wagner et al.,2019; Xu et al., 2007; Yuan Q et al., 2017; Min et al., 2021; Snitz et al., 2020; Rattay et al., 2022; Hyang-Beum et al., 2021; Wu et al., 2020; Conejero et al., 2021; Jang et al., 2022; Babulal et al., 2020; Said et al., 2022; Tsai et al., 2021; Wallon et al., 2021;
Wrong outcome	47	Delrieu et al., 2020; Ngwa et al., 2021; Nilsson et al., 2021; Stein et al., 2021; Mueller-Schmitz et al., 2020; Zagatt et al., 2022; Sullivan et al., 2021; Ngwa et al., 2022; Nadkarni et al., 2017; Villas-Boas et al., 2021; Ahn et al., 2020; Skillback et al., 2022; Lauretani et al., 2020; D'Souza et al., 2021; Lukkarinen et al, 2022; Cohelo et al., 2022; He et al., 2020a; Goncalves et al., 2020; He et al, 2020b; Shaaban et al., 2022; Chou et al., 2021; Bedada et al., 2021; Chelban et al., 2021; Taghdiri et al., 2020; Padilla et al., 2022; Craig et al., 2020; Rodziewicz-Flis et al., 2022; Morel et al., 2020; Kanemoto et al., 2021; Kim et al. 2020; Darrow et al., 2022; Dadar et al., 2021; Barreto et al., 2017; Bohnen et al., 2014; Dao et al., 2016; Del campo et al., 2016; Koychev et al., 2018; Leahey et al., 2007; Muller et al., 2013; Rochester et al., 2017; Schirinzi et al., 2018; Schultz et al., 2017; Schultz et al., 2015; Tian et al., 2017; Tian et al., 2018; Wennberg et al., 2016; Wennberg et al., 2017; Yoon et al., 2018
Wrong study design	5	Mayor et al., 2015; Komiyama et al., 1991; Vidoni et al, 2021; Ribeiro et al., 2021; Willis, 2020

Table S3. Criteria for the methodological risk of bias assessment of included articles and percentage of studies meeting these criteria.

Criteria items	Percentage of studies meeting criterion (%)
1. Were the criteria for inclusion in the sample clearly defined?	100
2. Were the study subjects and the setting described in detail?	71.4
3. Was the exposure measured in a valid and reliable way?	100
4. Were objective, standard criteria used for measurement of the condition?	-
5. Were confounding factors identified?	71.4
6. Were strategies to deal with confounding factors stated?	71.4
7. Were the outcomes measured in a valid and reliable way?	42.8
8. Was appropriate statistical analysis used?	85.6

Adapted from the Joanna Briggs Institute Critical Appraisal Tool for Systematic Reviews;

- : Not applicable criterion

Table S4. Risk of bias assessment of included articles.

Study	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Quality Score %	Risk Category
Bommarito et al. (2022) [1]	✓	✓	✓	-	✓	✓	✓	✓	100	Low Risk
Dougherty et al. (2021) [2]	✓	✓	✓	-	✓	✓	✓	✓	100	Low Risk
Hatcher-Martin et al. (2021) [3]	✓	✗	✓	-	✗	✗	✗	✗	28	High Risk
Jacob et al. (2022) [4]	✓	✓	✓	-	✓	✓	✗	✓	85	Low Risk
Knapstad et al. (2019) [5]	✓	✓	✓	-	✓	✓	✗	✓	85	Low Risk
Legdeur et al. (2021) [6]	✓	✓	✓	-	✓	✓	✓	✓	100	Low Risk
Tsai et al. (2021) [7]	✓	✗	✓	-	✗	✗	✗	✓	57	High Risk
Criterion Score %	100	71.4	100	-	71.4	71.4	42.8	85.6	-	-

Note that the total risk of bias score was calculated by dividing the number of criteria met in one study by the total number of criteria (i.e., 7). ✓: meet the methodological quality criterion; ✗: not meet the methodological quality criterion; the studies were considered as “low risk” when 75% of items were scored as “yes” (criterion met); Adapted from the Joanna Briggs Institute Critical Appraisal Tool for Systematic Reviews; -:Not applicable criterion. **Item 1: Were the criteria for inclusion in the sample clearly defined?; Item 2: Were the study subjects and the setting described in detail?; Item 3: Was the exposure measured in a valid and reliable way?; Item 4: Were objective, standard criteria used for measurement of the condition?; Item 5: Were confounding factors identified?; Item 6: Were strategies to deal with confounding factors stated?; Item 7: Were the outcomes measured in a valid and reliable way?; Item 8: Was appropriate statistical analysis used?**

References

- [1] Bommarito G, Garibotto V, Frisoni GB, Ribaldi F, Stampacchia S, Assal F, Armand S, Allali G, Griffa A (2022) The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging. *J Alzheimers Dis*.
- [2] Dougherty RJ, Ramachandran J, Liu F, An Y, Wanigatunga AA, Tian Q, Bilgel M, Simonsick EM, Ferrucci L, Resnick SM, Schrack JA (2021) Association of walking energetics with amyloid beta status: Findings from the Baltimore Longitudinal Study of Aging. *ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING* **13**.
- [3] Hatcher-Martin JM, McKay JL, Pybus AF, Sommerfeld B, Howell JC, Goldstein FC, Wood L, Hu WT, Factor SA (2021) Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis. *NPJ PARKINSONS DISEASE* **7**.
- [4] Jacob ME, O'Donnell A, Samra J, Gonzales MM, Satizabal C, Pase MP, Murabito JM, Beiser A, Seshadri S (2022) Grip Strength, Gait Speed and Plasma Markers of Neurodegeneration in Asymptomatic Middle-aged and Older Adults. *JOURNAL OF FRAILTY & AGING*.
- [5] Knapstad MK, Steihaug OM, Aaslund MK, Nakling A, Naterstad IF, Fladby T, Aarsland D, Giil LM (2019) Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study. *J Geriatr Phys Ther* **42**, E122-E128.
- [6] Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, ten Kate M, Gordon MF, Novak G, Barkhof F, van Berckel BNM, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ (2021) What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. *JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES* **76**, 1499-1511.
- [7] Tsai C-L, Erickson KI, Sun HS, Kuo Y-M, Pai M-C (2021) A cross-sectional examination of a family history of Alzheimer's disease and ApoE epsilon 4 on physical fitness, molecular biomarkers, and neurocognitive performance. *Physiology & Behavior* **230**, 9.

